Supplementary Data:

Supplementary Figure S1

Supplementary Figure S1. Inflammatory and proangiogenic genes are upregulated in the lungs during cancer metastatic progression. (A) Images of tumor cell colonies from clonogenic metastatic assay from the lungs harvested at several time points after 4T1 cells injection into the mammary fat pad; (B) Quantification of A, lungs from tumor-free mice (TF) are included as negative controls; (C) Images of the lungs at time points as in A; (D) Lung metastases counts by a dissection microscope. (E-G) Genes differentially expressed in the lungs at sequential steps on lung metastatic progression. Data are representative of one experiment with five mice per cohort.

Supplementary Figure S2

Supplementary Figure S2. Downregulation of proangiogenic factors by C5aR1 blockade.
(A) Fold change in *Mmp9* lung expression in tumor-bearing mice (TB) treated PBS and PMX53 relative to tumor-free mice; (B) Fold change in *Mmp9* expression in MDSC isolated from the lungs of TB treated with PMX53 relative to expression in MDSC from TB injected with PBS. *P<0.05 by t-test, Data are representative one experiment with n=6-8 mice. (C) Fold change in plasma levels of angiogenesis regulators in 4T1 tumor-bearing mice treated with PMX53 relative to tumor-free (TF) mice. Red star-IL-1β. The treatment was begun 4 days after tumor cells' injection and the experiment was terminated at day 15. Samples from ten mice were pooled for this assay.

Supplementary Figure S3

Supplementary Figure S3. Sunitinib reduces lung metastasis and growth of 4T1 tumors but does not affect vascular density of the lungs. (A) Lung metastases in mice treated with sunitinib or placebo (DMSO/PBS); (B) Growth of primary 4T1 tumors in mice as in A; (C) Volume of excised primary tumors in mice as in A; (D) Lung vascular density based on CD31 immunofluorescence. **$P<0.01$, *$P<0.05$ by t-test in A, C, and D or Two-Way ANOVA in B. Data are representative of one experiment with $n_1=4$ and $n_2=8$ mice.